Industry-Sponsored Research Week
Industry-Sponsored Research Management

Mount Sinai renews research deal with Pfizer


By David Schwartz
Published: July 11th, 2017

 The Icahn School of Medicine at Mount Sinai and Pfizer Inc.’s Centers for Therapeutic Innovation (CTI) have renewed an agreement designed to identify and advance new drug candidates linked to major diseases, such as cancer, rheumatoid arthritis, Crohn’s disease, colitis, heart failure, Alzheimer’s disease, and cystic fibrosis.

In 2010, Mount Sinai became one of the first academic medical centers to enter into a collaboration with CTI, which is focused on speeding the commercialization of new drugs. The collaboration allows Mount Sinai investigators to submit research proposals to CTI, and for CTI to provide funding and drug development expertise as a means of advancing new therapies. To date, five Mount Sinai projects have been funded through this process, focusing mainly on diabetes, autoimmune disease and cancer.

Project proposals are chosen through a rigorous vetting process by a steering committee composed of leading Pfizer and Mount Sinai scientists, which selects only projects with strong potential to address an unmet medical need. Resulting research collaborations complement the biological expertise at Mount Sinai with Pfizer’s drug discovery and development capabilities, including the ability to create antibodies and small-molecules.

“Best–in-class translational research rarely occurs in a vacuum. Mount Sinai is dedicated to bringing therapeutics from the bench to the bedside, to improve health outcomes. Capitalizing on the synergies between industry and academic capabilities brings us closer to this goal,” said Erik Lium, PhD, senior vice president of Mount Sinai Innovation Partners (MSIP), the technology development and commercialization arm of Mount Sinai.

According to CTI’s Chief Scientific Officer, Anthony J. Coyle, PhD, “CTI and Mount Sinai have a long-standing and exceptional track record of research collaboration aimed at bringing early-stage medical discoveries towards the clinic. This renewed commitment will further enhance our alliance.”

Source: Newswise

Posted under: Industry-Sponsored Research Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment